Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
COLUMBIA, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that The Nasdaq Stock Market LLC has approved its application to list its common stock on The Nasdaq Global Market. Osiris’s common stock will commence trading at the market open today, Wednesday, August 1, 2018, under the ticker symbol “OSIR”.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. We have achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix®, BIO4® and Cartiform®. We continue to advance our research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. Osiris®, Grafix® and Cartiform® are our trademarks. BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation. More information can be found on the Company’s website, . (OSIR-G)
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
